$GRI 4 SEC Filings

Filed On	Filing
22 Sep 2025	Form 4: Kelly Leanne, Chief Financial Officer Granted 43,222 Stock Option (Right to Buy)
22 Sep 2025	Form 4: Szekeres David Leslie, Director Granted 39,897 Stock Option (Right to Buy)
22 Sep 2025	Form 4: Baker David Charles, Director Granted 23,605 Stock Option (Right to Buy)
22 Sep 2025	Form 4: Simpson Camilla V, Director Granted 23,605 Stock Option (Right to Buy)
22 Sep 2025	Form 4: Chaturvedi Vipin, Chief Scientific Officer Granted 43,222 Stock Option (Right to Buy)
22 Sep 2025	Form 4: Rongen Roelof, Director Granted 23,605 Stock Option (Right to Buy)
22 Sep 2025	Form 4: Hertz Walter Marc, Director Granted 103,067 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Hertz Walter Marc, Director Granted 26,688 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Szekeres David Leslie, Director Granted 10,276 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Baker David Charles, Director Granted 5,994 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Rongen Roelof, Director Granted 5,994 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Chaturvedi Vipin, Chief Scientific Officer Granted 11,854 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Simpson Camilla V, Director Granted 5,994 Stock Option (Right to Buy)
27 Aug 2025	Form 4: Kelly Leanne, Chief Financial Officer Granted 11,854 Stock Option (Right to Buy)
14 Aug 2025	Form 4: Simpson Camilla V, Director Granted 4,527 Stock Option (Right to Buy)
14 Aug 2025	Form 4: Baker David Charles, Director Granted 4,527 Stock Option (Right to Buy)
14 Aug 2025	Form 4: Rongen Roelof, Director Granted 4,527 Stock Option (Right to Buy)
14 Aug 2025	Form 4: Szekeres David Leslie, Director Granted 7,545 Stock Option (Right to Buy)
24 Jan 2025	Form 4: Kelly Leanne, Chief Financial Officer Granted 43,319 Stock Option (Right to Buy) ($29.7K)
24 Jan 2025	Form 4: Chaturvedi Vipin, Chief Scientific Officer Granted 43,319 Stock Option (Right to Buy) ($29.7K)

Comments